NASDAQ: DFTX

Definium Therapeutics (DFTX) Stock Analysis & Forecast

Nov 13 close

$32.08−0.92 (−2.8%)

Gekko Brief

AI summaryNov 9 close

Definium Therapeutics rose this week on positive Phase 3 results for lead candidate DT120, which met primary and secondary endpoints in generalized anxiety disorder and major depressive disorder studies presented at the 2026 NEI Fall Congress. The company also reported Q3FY26 results with a net loss of $51.0 million, narrowed from $67.3 million a year earlier, secured two FDA Breakthrough Therapy designations for DT120, and outlined plans for an NDA filing in early 2027. Separately, an investment firm disclosed a 6.5% passive stake in the company as of September 30, 2026.

DFTX closed at $35.39, up 6.4%, sitting between its 50-day average of $36.49 and 200-day average of $30.10. The stock's six-month return stands at 65.4% and its one-year return at 212.1%, though the three-month return is -13.5%. The GekkoIndex reads 60.4, placing the stock in the Accumulation zone, down 4.2 over five days. Price sits 23.1% below the Gekko Fair Value of $46.02.

No confirmed earnings date is currently on the calendar; the last report, on 6 August 2026, showed an EPS beat against estimate with a 3.9% reaction, against an average absolute reaction of 7.3% across prior quarters. Smart money activity shows no insider, Congress or unusual options signals in their respective windows, though one billionaire holder is noted. Analyst coverage is uniformly bullish, with all 15 firms rating the stock buy and a consensus target of $72.56. Seasonally, the next 20 trading days have averaged +3.4% over 5 years, rising in 4 of them, worth noting alongside the stock's typical 20-day move of 13.1%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Definium Therapeutics price vs fair value

$45.59$32.08Nov ’25May ’26Nov ’26
Close $32.08200-day averageGekko Fair Value $45.59

Definium Therapeutics quick facts

Market cap
$4.39B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$2.92
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
2.21
Volume
777,303 avg 1.64M
1-year return
+164.3%
Typical daily move
±7%
Typical 20-day move
±13.1%
50-day average
$36.07
200-day average
$30.43
Next earnings
Feb 25 after close
Shares outstanding
136.9M
52-week range
$10.46$49.70

Definium Therapeutics swing-trade checklist

Definium Therapeutics scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $32.08 sits between the 50-day ($36.07) and 200-day ($30.43) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    63.1, Accumulation

    Reading 63.1 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    29.6% below

    Price is 29.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −4.4% on average

    From this point in the calendar, the next 20 trading days averaged −4.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Definium Therapeutics stock chart and price history

Definium Therapeutics closed at $32.08 on Nov 13, 2026, +164.3% over the past year, inside a 52-week range of $10.46 to $49.70.

Close50-day average200-day averageVolume
Definium Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$10$20$40$50DecJan 2026FebMarAprMayJunJulAugSepOctNov32.08

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−6.4%
3 months
−29.1%
6 months
+52.8%
1 year
+164.3%
The full DFTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DFTX in Gekko

Follow Definium Therapeutics through every session

Put DFTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track DFTX in GekkoFree for 7 days. No credit card required.

About Definium Therapeutics

Definium Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for brain health and neurological conditions. Its work centers on experimental drug candidates rather than approved products, with the aim of addressing disorders that affect cognition and behavior. The company is best known for its pipeline of compounds still under clinical investigation rather than any commercialized therapy.

Among its lead programs is MM120, now in Phase 3 trials for generalized anxiety disorder and attention deficit hyperactivity disorder. It is also advancing MM402, an R-enantiomer of MDMA, through Phase 1 testing aimed at the core symptoms of autism spectrum disorder. These programs suggest a business built around drug development milestones rather than steady product sales, with progress tied to clinical trial outcomes.

Definium Therapeutics is headquartered in New York, New York. Its shares trade on the NASDAQ under the ticker DFTX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
definiumtx.com

Definium Therapeutics GekkoIndex: the smart money zone

Definium Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.1, in the Accumulation zone, down 1.2 points over five sessions.

010063.1Accumulation

Down 1.2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying40+1.6%+6.0%+12.1%+38.8%
Accumulation (current zone)182+1.5%+1.7%+4.2%+16.1%
Neutral397+2.1%+4.9%+9.7%+21.6%
Distribution64+4.9%+8.8%+17.6%+26.4%
Selling190.0%+3.3%+6.1%+6.1%

Average DFTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the DFTX price, zone by zone.Track DFTX in Gekko

Is Definium Therapeutics stock overvalued? Gekko Fair Value

Definium Therapeutics trades 29.6% below Gekko Fair Value of $45.59, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Definium Therapeutics shares are worth, recalculated every trading day.

$45.59

Gekko Fair Value, Nov 14, 2026

29.6% Undervalued

At the end of Aug 2026 the price was 30.6% below the estimate.

Gekko Fair ValueShare price, month end
$46$32Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open DFTX in Gekko

Definium Therapeutics insider and Congress trading

No open-market insider purchases were filed for Definium Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for DFTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every DFTX insider filing, plotted on the chart in Gekko.Open DFTX in Gekko

Congress trades last 90 days

No trades in DFTX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for DFTX, plotted on the chart in Gekko.Open DFTX in Gekko

Buybacks

Definium Therapeutics has been buying back its own shares.

Bought back, quarter ended Mar 31, 2022
$407K
As a share of market cap
0.01%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds DFTX.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Definium Therapeutics earnings: next date and track record

Definium Therapeutics reports on Feb 25, 2027, after the close (102 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±7.3%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+25.8%Nov ’24+7.1%Mar ’25−6.7%May ’25−6.5%Jul ’25+1.5%Nov ’25−1.0%Feb ’26−5.8%May ’26+3.9%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026−$1.44
est −$0.54
−166.2%——+3.9%
May 7, 2026−$0.71
est −$0.48
−48.9%——−5.8%
Feb 26, 2026−$0.45
est −$0.45
0.0%——−1.0%
Nov 6, 2025−$0.78
est −$0.52
−50.0%——+1.5%
Jul 31, 2025−$0.50
est −$0.38
−31.6%——−6.5%
May 8, 2025−$0.35
est −$0.36
+2.8%——−6.7%
Mar 6, 2025−$0.41
est −$0.31
−32.3%——+7.1%
Nov 7, 2024−$0.18
est −$0.28
+35.7%——+25.8%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Definium Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Definium Therapeutics is $72.78, +126.9% from the last close, from 14 firms rating the stock in the last 90 days.

$72.78consensus 12-month target, +126.9% from the last close
Low $55High $91
Buy14
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 14 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 12JonesTradingBuy, reiterated$90+180.5%
Nov 11Wells FargoBuy, maintained$72+124.4%
Nov 10Piper SandlerBuy, reiterated$75+133.8%
Nov 10OppenheimerBuy, maintained$75+133.8%
Nov 10NeedhamBuy, reiterated$66+105.7%
+4.2%average 20-day move after past Accumulation readings
−4.4%average move over the next 20 trading days in the last 5 years
±7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Definium Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Definium Therapeutics averaged −4.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−30.6%2021−4.6%2022+23.3%2023−14.7%2024+6.4%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.5%1 of 5
Next 10 trading days+1.9%2 of 5
Next 15 trading days+3.0%2 of 5
Next 20 trading days−4.4%2 of 5
Next 30 trading days−4.2%2 of 5

For scale, DFTX’s typical 20-trading-day move in either direction is about 13.1%.

Definium Therapeutics market cap and key statistics

Definium Therapeutics’s market cap is $4.39B and revenue of $0 over the last twelve months.

Valuation

Market cap
$4.39B
EPS, TTM
−$2.92
Gekko Fair Value
$45.59

Trading

Volume
777,303
Avg volume, 20 days
1.64M
52-week high
$49.70
52-week low
$10.46
Shares outstanding
136.9M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-61.4%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
2.21
Typical daily move
±7%
Typical 20-day move
±13.1%

Definium Therapeutics peers

Definium Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Definium Therapeutics stock FAQ

What is Definium Therapeutics’s market cap?

Definium Therapeutics’s market cap is $4.39B at the Nov 13, 2026 close of $32.08, with 136.9M shares outstanding.

What is the Definium Therapeutics stock forecast?

The consensus analyst 12-month price target for Definium Therapeutics is $72.78, +126.9% from the last close. Of the 14 firms that rated the stock in the last 90 days, 14 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Definium Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Definium Therapeutics is undervalued: the Nov 13, 2026 close of $32.08 is 29.6% below Gekko Fair Value of $45.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Definium Therapeutics report earnings next?

Definium Therapeutics is expected to report on Feb 25, 2027, after the market closes (102 days away). Analysts expect earnings of −$0.51 per share. Definium Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 7.3% on average across the report.

What is Definium Therapeutics’s 52-week high and low?

Definium Therapeutics’s 52-week high is $49.70 and its 52-week low is $10.46; it closed at $32.08 on Nov 13, 2026, +164.3% over the past year.

Is Definium Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Definium Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.